International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, F-69008 Lyon, France.
Carcinogenesis. 2013 Sep;34(9):1955-67. doi: 10.1093/carcin/bgt212. Epub 2013 Jun 7.
Remarkable progress in the field of epigenetics has turned academic, medical and public attention to the potential applications of these new advances in medicine and various fields of biomedical research. The result is a broader appreciation of epigenetic phenomena in the a etiology of common human diseases, most notably cancer. These advances also represent an exciting opportunity to incorporate epigenetics and epigenomics into carcinogen identification and safety assessment. Current epigenetic studies, including major international sequencing projects, are expected to generate information for establishing the 'normal' epigenome of tissues and cell types as well as the physiological variability of the epigenome against which carcinogen exposure can be assessed. Recently, epigenetic events have emerged as key mechanisms in cancer development, and while our search of the Monograph Volume 100 revealed that epigenetics have played a modest role in evaluating human carcinogens by the International Agency for Research on Cancer (IARC) Monographs so far, epigenetic data might play a pivotal role in the future. Here, we review (i) the current status of incorporation of epigenetics in carcinogen evaluation in the IARC Monographs Programme, (ii) potential modes of action for epigenetic carcinogens, (iii) current in vivo and in vitro technologies to detect epigenetic carcinogens, (iv) genomic regions and epigenetic modifications and their biological consequences and (v) critical technological and biological issues in assessment of epigenetic carcinogens. We also discuss the issues related to opportunities and challenges in the application of epigenetic testing in carcinogen identification and evaluation. Although the application of epigenetic assays in carcinogen evaluation is still in its infancy, important data are being generated and valuable scientific resources are being established that should catalyse future applications of epigenetic testing.
在表观遗传学领域取得了显著进展,这引起了学术界、医学界和公众对这些医学新进展和各个生物医学研究领域的潜在应用的关注。其结果是,人们更加了解表观遗传现象在常见人类疾病(尤其是癌症)发病机制中的作用。这些进展也为将表观遗传学和表观基因组学纳入致癌物识别和安全评估提供了令人兴奋的机会。目前的表观遗传学研究,包括主要的国际测序项目,有望提供建立组织和细胞类型“正常”表观基因组以及可以评估致癌物暴露的表观基因组生理变异性的信息。最近,表观遗传事件已成为癌症发展的关键机制,虽然我们在《专论》第 100 卷中的搜索结果表明,到目前为止,表观遗传学在国际癌症研究机构(IARC)专论中评估人类致癌物方面仅发挥了适度作用,但表观遗传数据在未来可能会发挥关键作用。在这里,我们回顾了(i)IARC 专论计划中表观遗传学在致癌物评估中的当前纳入状况,(ii)表观遗传致癌物的潜在作用模式,(iii)当前用于检测表观遗传致癌物的体内和体外技术,(iv)基因组区域和表观遗传修饰及其生物学后果,以及(v)评估表观遗传致癌物的关键技术和生物学问题。我们还讨论了在致癌物识别和评估中应用表观遗传学检测的机会和挑战相关问题。尽管在致癌物评估中应用表观遗传学检测仍处于起步阶段,但正在生成重要数据并建立有价值的科学资源,这应会促进未来对表观遗传学检测的应用。